エマパルマブによるCAR-T細胞関連毒性の予防
CAR-T 細胞関連毒性の予防を目的としたエマパルマブの第 2 相試験
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).
The research study involves the following study interventions:
- Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
- Axicabtagene Ciloleucel or Lisocabtagene Maraleucel
- Emapalumab
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is a phase 2 multi-center, open label study that is evaluating the safety and efficacy of emapalumab in preventing toxicities associated with FDA Approved, CD19-directed CAR-T in subjects with second- or third-line large B-cell non-Hodgkin's lymphoma.
A phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
The U.S. Food and Drug Administration (FDA) has not approved emapalumab for the participants specific disease, but it has been approved for other uses.
The U.S. FDA has approved axicabtagene ciloleucel and lisocabtagene maraleucel for the participants specific disease.
This research study procedures include screening for eligibility, study treatment including collection of T cells (leukapheresis), lymphodepleting chemotherapy, treatment with emapalumab and axicabtagene ciloleucel or lisocabtagene maraleucel, and follow-up evaluations.
Once study treatment is completed, the participants will be followed for up to 24 months.
It is expected that about 28 people will take part in this research study.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:Matthew Frigault, MD
- 電話番号:(617) 643-6175
- メール:MFRIGAULT@partners.org
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- 募集
- Massachusetts General Hospital
-
主任研究者:
- Matthew Frigault, MD
-
コンタクト:
- Matthew Frigault, MD
- 電話番号:617-643-6175
- メール:MFRIGAULT@partners.org
-
Boston、Massachusetts、アメリカ、02215
- まだ募集していません
- Dana-Farber Cancer Institute
-
コンタクト:
- Caron Jacobson, MD
- 電話番号:(617)-632-5847
- メール:Caron_Jacobson@DFCI.HARVARD.EDU
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Or adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
-
At least 1 measurable lesion per Lugano at time of screening.
-
Age 18 or older
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Adequate renal, hepatic, pulmonary and cardiac function defined as:
- ANC ≥1000/uL
- Platelet count ≥50,000/uL
- Absolute lymphocyte count ≥100/uL
- Creatinine clearance (as estimated by Cockcroft Gault or CKD-EPI) ≥ 30 mL/min
- Serum ALT/AST ≤2.5 per institutional ULN
- Total bilirubin ≤1.5 mg/dl, except in subjects with Gilbert's syndrome.
- Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ECG findings
- Baseline oxygen saturation >92% on room air.
-
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential).
-
Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
-
History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years.
-
Autologous stem cell transplant within 6 weeks of planned CAR-T infusion.
-
History of allogeneic stem cell transplantation.
-
Presence of uncontrolled fungal, bacterial, viral, or other infection at time of screening.
-
Known history of acute or chronic active hepatitis B or C infection. Subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines.
- Patients should also be negative for latent Tb, CMV (NAT), EBV (NAT) and adenovirus (NAT) by PCR testing.
-
No evidence of active CNS disease regardless of prior CNS history.
-
History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage within 6 months of enrollment.
-
History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.
-
History of symptomatic pulmonary embolism within 3 months of enrollment; ongoing anticoagulation is allowed if beyond 3 months.
-
Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.
-
History of allergic reactions or severe immediate hypersensitivity reaction to any of the agents used in this study or compounds of similar chemical or biologic composition.
-
Females who are pregnant or breastfeeding or female or male participants who are not willing to practice birth control from the time of consent through 6 months after the completion of CAR-T
-
In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.
-
History of autoimmune disease requiring ongoing systemic immunosuppression. Steroids are allowed up to 5mg predinosine-equivalent for adrenal insufficiency.
-
Receipt of a BCG vaccine within 12 weeks prior to Screening.
-
Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screeing.
-
Participants who are receiving any other investigational agents for this condition.
-
Patients anticipated to require canakinumab, JAK inhibitors, TNF inhibitors, and tocilizumab for non-CAR-T management of baseline autoimmune/inflammatory disease at the time of emapalumab initiation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Cohort 1a
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. Patients will receive emapalumab 3mg/kg on day -1. FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes. |
An interferon gamma (IFNγ) blocking antibody
他の名前:
Alkylating agent Purine antagonist antimetabolite Autologous treatment |
|
実験的:Cohort 1b
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes. Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2. Patients will receive emapalumab 3mg/kg on day +1. |
An interferon gamma (IFNγ) blocking antibody
他の名前:
Alkylating agent Purine antagonist antimetabolite Autologous treatment Corticosteroid |
|
実験的:Cohort 2a
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. Patients will receive emapalumab 3mg/kg on day -1. Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes. |
An interferon gamma (IFNγ) blocking antibody
他の名前:
Alkylating agent Purine antagonist antimetabolite Autologous treatment |
|
実験的:Cohort 2b
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes. Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2. Patients will receive emapalumab 3mg/kg on day +1. |
An interferon gamma (IFNγ) blocking antibody
他の名前:
Alkylating agent Purine antagonist antimetabolite Corticosteroid Autologous treatment |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of grade 2+ CRS per ASTCT
時間枠:Day -1 to 24 months post treatment
|
Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). All participants will be monitored and assessed for grade 2+ cytokine release syndrome (CRS) for 24 months after post treatment. |
Day -1 to 24 months post treatment
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rate and severity of ICANS as per ASTCT
時間枠:30 days
|
Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). The rate and severity of immune cell associated neurotoxicity syndrome (ICANS) within the first 30 days of infusion. |
30 days
|
|
Objective response rate (ORR)
時間枠:Day -1 to 24 months post treatment
|
The incidence of either a complete response or a partial response by Lugano. All subjects that do not meet the criteria for an objective response by the analysis data cutoff date will be considered non-responders. |
Day -1 to 24 months post treatment
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Duration of response (DOR)
時間枠:From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
Among subject who experience an objective response the date of their first objective response to disease progression per Lugano or death regardless of cause. Subjects not meeting the criteria for progression or death by the analysis data cutoff date will be censored at their last evaluable disease assessment date and their response will be noted as ongoing. |
From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
|
Progression-free Survival (PFS)
時間枠:From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
The time from the CAR-T infusion date to the date of disease progression per Lugano or death from any cause. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date. |
From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
|
Overall survival (OS)
時間枠:From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment
|
The time from CAR-T infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date. |
From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Matthew Frigault, MD、Massachusetts General Hospital
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 新生物
- 免疫系疾患
- 組織型別の新生物
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- リンパ腫、B細胞
- リンパ腫
- ヘミックおよびリンパ疾患
- リンパ腫、大型B細胞、びまん性
- リンパ腫、非ホジキン
- リンパ腫、濾胞性
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 炭化水素
- 多環式化合物
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 妊娠
- 妊娠
- ステロイド
- 融合リング化合物
- ステロイド、フッ素化
- ホスホルアミドマスタード
- 窒素マスタード化合物
- マスタード化合物
- 炭化水素、ハロゲン化
- ホスホラミド
- 有機リン化合物
- 妊娠症
- デキサメタゾン
- シクロホスファミド
- 抗体、モノクローナル
- フルダラビンリン酸
- axicabtagene ciloleucel
- Emapalumab
その他の研究ID番号
その他の研究ID番号
- 24-317
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD 共有時間枠
Data can be shared no earlier than 1 year following the date of publication
IPD 共有アクセス基準
Contact the Partners Innovations team at http://www.partners.org/innovation
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。